ASX:BDABOD Australia Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding BOD Australia Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add A$0.32 -0.01 (-3.08 %) (As of 05/13/2020) Add Compare Share Today's RangeA$0.32Now: A$0.32▼A$0.3350-Day RangeA$0.24MA: A$0.29▼A$0.3552-Week RangeA$0.12Now: A$0.32▼A$0.72Volume75,095 shsAverage VolumeN/AMarket Capitalization$28.78 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsEarningsInsider TradesHeadlines BOD Australia Limited operates as a developer, manufacturer, distributor, and marketer of plant-based medicinal cannabis, health and supplement products, and cosmetic solutions primarily in Australia. Its medicines portfolio includes Enterofytol for treating irritable bowel syndrome; and SediStress, which is used for the reduction of stress and anxiety. The company distributes its products through a channel network of approximately 900 pharmacies. It offers products under the SediStress, BIOEFFECT, PINPOINT, Flexofytol, Enterofytol, MamaCare, and Pommade Devine brands. Bod Australia Limited has a research collaboration agreement with Cannabis Access Clinics. The company is based in Double Bay, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for BOD Australia. Previous Next 2.3 Community Rank Outperform VotesBOD Australia has received 13 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBOD Australia has received 15 “underperform” votes. (Add your “underperform” vote.)Community SentimentBOD Australia has received 53.57% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about BOD Australia and other stocks. Vote “Outperform” if you believe BDA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BDA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBOD Australia does not currently pay a dividend.Dividend GrowthBOD Australia does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BOD Australia insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of BOD Australia is -3.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BOD Australia is -3.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBOD Australia has a P/B Ratio of 3.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.46 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Household & Personal Products Sub-IndustryN/A SectorConsumer Defensive Current SymbolASX:BDA Previous Symbol CUSIPN/A CIKN/A Webbodaustralia.com Phone61 2 9199 5018Debt Debt-to-Equity RatioN/A Current Ratio4.88 Quick Ratio4.43Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.27 million Price / Sales12.68 Cash FlowA$0.09 per share Price / Cash Flow3.54 Book ValueA$0.09 per share Price / Book3.66Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares91,369,504Market Cap$28.78 million Next Earnings DateN/A OptionableNot Optionable Receive BDA News and Ratings via Email Sign-up to receive the latest news and ratings for BDA and its competitors with MarketBeat's FREE daily newsletter. BOD Australia (ASX:BDA) Frequently Asked Questions How has BOD Australia's stock been impacted by COVID-19 (Coronavirus)? BOD Australia's stock was trading at A$0.19 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BDA shares have increased by 65.8% and is now trading at A$0.32. View which stocks have been most impacted by Coronavirus. How were BOD Australia's earnings last quarter? BOD Australia Ltd (ASX:BDA) announced its quarterly earnings results on Thursday, February, 28th. The company reported ($0.05) earnings per share for the quarter. View BOD Australia's earnings history. Has BOD Australia been receiving favorable news coverage? News coverage about BDA stock has been trending positive this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. BOD Australia earned a news sentiment score of 2.4 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutBOD Australia. Who are some of BOD Australia's key competitors? Some companies that are related to BOD Australia include MAV Beauty Brands (MAV), Accrol Group (ACRL), Mediland Pharm (MPH), Acme United (ACU), Warpaint London (W7L), Pental (PTL), Brand Architekts Group (BAR), Integumen (SKIN), Orchids Paper Products (TIS), Skin Elements (SKN), Beiersdorf (BDRFF), Beiersdorf Aktiengesellschaft (BDRFY), Biologix Hair (BLGX), Dogness International (DOGZ) and ESSITY AKTIEBOL/S (ESSYY). View all competitors. What other stocks do shareholders of BOD Australia own? Based on aggregate information from My MarketBeat watchlists, some companies that other BOD Australia investors own include Syrah Resources (SYR), MGC Pharmaceuticals (MXC), Medlab Clinical (MDC), Lynas (LYC), iSignthis (ISX), Eclipx Group (ECX), Botanix Pharmaceuticals (BOT) and Auscann Group (AC8). Who are BOD Australia's key executives? BOD Australia's management team includes the following people: Ms. Joanne Patterson, CEO, Director & Member of Medical Advisory BoardMr. Craig Weller, COO & Member of Medical Advisory BoardMr. George Livery, Exec. Chairman (Age 52)Dr. Adele Hosseini, Chief Scientific Officer & Member of Medical Advisory BoardMr. Stephen Thompson, Exec. Director What is BOD Australia's stock symbol? BOD Australia trades on the ASX under the ticker symbol "BDA." What is BOD Australia's stock price today? One share of BDA stock can currently be purchased for approximately A$0.32. How big of a company is BOD Australia? BOD Australia has a market capitalization of $28.78 million and generates $2.27 million in revenue each year. What is BOD Australia's official website? The official website for BOD Australia is bodaustralia.com. How can I contact BOD Australia? The company can be reached via phone at 61 2 9199 5018. This page was last updated on 6/6/2020 by MarketBeat.com Staff
